Compare Moderna, Inc. (MRNA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs J M Smucker Co — how do they compare? Moderna, Inc. trades at $221.7 (market cap $78.65B), while J M Smucker Co trades at $119.8 (market cap $12.76B). The key difference: Moderna, Inc. is far larger — about 6.2× J M Smucker Co's market cap, and J M Smucker Co pays a 3.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and J M Smucker Co for 74 Days on average.
| MRNA | SJM | |
|---|---|---|
Market Cap | $78.65B | $12.76B |
Volume | 37,373,437 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $203.46 | $132.34 |
52-Week Low | $22.36 | $89.53 |
Typical Hold Time | 59 Days | 74 Days |
Enterprise Value | $74.80B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
SJM stock trades at $119.27, up 2.88% today, with a bullish technical signal from moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2025 results were impacted by a net loss of $1.23B. Analyst consensus is positive with a $138.23 price target, representing 16% upside potential. Recent news highlights strong execution and raised 2027 guidance, while technical indicators show support at $118 and resistance at $120.
The outlook remains cautiously optimistic with earnings momentum and raised guidance supporting upside, but investors face risks from volatile profitability, high debt levels, and competitive pressures in consumer staples. The stock offers value with reasonable P/S and EV/EBITDA multiples, though the elevated P/E ratio requires sustained earnings improvement to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
